The NENF Polyclonal Antibody (PAC063527) is a high-quality antibody designed for research involving NENF, a neudesin neurotrophic factor associated with neuronal development and function. This antibody, produced in rabbits, is highly specific and reactive with human samples, making it ideal for use in various research applications, including Western blotting. NENF is a key player in the regulation of neuronal growth and survival, making it a valuable target for studies in neuroscience and neurodegenerative diseases. By binding to the NENF protein, this antibody enables accurate detection and analysis in different cell types, providing valuable insights into the role of NENF in neuronal physiology and pathology.
Research into NENF is essential for understanding its involvement in various neurological disorders, such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. By exploring the function of NENF, researchers can uncover potential therapeutic targets and develop innovative approaches for the treatment of these debilitating diseases.
Antibody Name:
NENF Antibody (PACO63527)
Antibody SKU:
PACO63527
Size:
50ul
Host Species:
Rabbit
Tested Applications:
ELISA, IHC
Recommended Dilutions:
ELISA:1:2000-1:10000, IHC:1:20-1:200
Species Reactivity:
Human
Immunogen:
Peptide sequence from Human Neudesin protein (149-167AA)
IHC image of PACO63527 diluted at 1:100 and staining in paraffin-embedded human colon cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
IHC image of PACO63527 diluted at 1:100 and staining in paraffin-embedded human heart tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
Background:
Acts as a neurotrophic factor in postnatal mature neurons enhancing neuronal survival. Promotes cell proliferation and neurogenesis in undifferentiated neural pro-genitor cells at the embryonic stage and inhibits differentiation of astrocyte. Its neurotrophic activity is exerted via MAPK1/ERK2, MAPK3/ERK1 and AKT1/AKT pathways. Neurotrophic activity is enhanced by binding to heme. Acts also as an anorexigenic neurotrophic factor that contributes to energy balance (By similarity). Plays a role in the human tumorigenesis.
Synonyms:
Neudesin (Cell immortalization-related protein 2) (Neuron-derived neurotrophic factor) (Protein GIG47) (Secreted protein of unknown function) (SPUF protein), NENF, CIR2 SPUF
UniProt Protein Function:
NENF: Displays neurotrophic activity and activates phosphorylation of MAPK1/ERK2, MAPK3/ERK1 and AKT1/AKT in primary cultured neurons. Does not have mitogenic activity in primary cultured astrocytes. May play a role on neuronal differentiation and may have a transient effect on neural cell proliferation in neural precursor cells. Neurotrophic activity is enhanced by binding to heme. Belongs to the cytochrome b5 family. MAPR subfamily.Protein type: Secreted; Secreted, signal peptideChromosomal Location of Human Ortholog: 1q32.3Cellular Component: endomembrane system; extracellular space; membraneMolecular Function: growth factor activity; metal ion bindingBiological Process: negative regulation of appetite; positive regulation of MAPK cascade
UniProt Protein Details:
NCBI Summary:
This gene encodes a neurotrophic factor that may play a role in neuron differentiation and development. A pseudogene of this gene is found on chromosome 12. Alternate splicing of this gene results in multiple transcript variants. [provided by RefSeq, Jan 2009]
